Posted on

Mario’s secret revealed 🍄

Psyched Wellness Provides Update on Anti-Inflammatory Study with the National Research Council of Canada

The iconic red and white spotted mushroom (officially called Amanita Muscaria and unofficially called the Super Mario mushroom) is showing potential to treat arthritis.

Psyched Wellness (PSYC) is working with the National Research Council of Canada (NRC) to study the mushroom’s properties. It doesn’t contain psilocybin, but has a different psychoactive component called muscimol.

Preliminary data suggests that Amantia Muscaria could reduce inflammation in the skin, gut, brain, and lungs. The company believes it has potential to treat chronic inflammatory conditions like arthritis.

Maybe that’s why Mario can jump so high without destroying his joints 😉

PDF of article

Posted on

First commercial study of LSD in 40 years

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

MindMed’s LSD-based compound received FDA clearance, allowing the company to proceed with a trial that will be the first commercial study of LSD in over 40 years.

The study will assess 200 patients with generalized anxiety disorder to find the optimal dose of the formulation. 

Shares of MNMD spiked 30% following the announcement 💰

PDF of article

Posted on

Add some ecstasy to your sex life

Subjective effects of MDMA (‘Ecstasy’) on human sexual function

Over 90% of people experienced increased sexual desire and satisfaction after taking MDMA. But that’s not the only way it can improve your sex life.

Mindcure (MCUR) is studying MDMA-assisted-therapy as a treatment for Hypoactive Sexual Desire Disorder (HSDD), which is characterized by low sex drive and emotional distress. 

The goal is to use MDMA to get to the root cause of the issue, which may be a history of negative sexual experiences and relationships or struggles with self worth or body image.

pubmed logo

PDF of article

Posted on

Microdosing DMT

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

Algernon Pharmaceuticals (AGN) found that microdoses of DMT can increase the growth of neurons in the brain by up to 40%. An upcoming study will see if this can benefit stroke patients.

Phase I of the study, which is awaiting approval in the UK, will determine the maximum amount of DMT that can be taken without producing a psychedelic effect. Phase II will test repeated doses on acute and recovering stroke patients.

Algernon Logo 1.png

PDF of article

Posted on

Microdosing eases depression

Wesana Health Announces Positive Findings From Animal Study on Novel Depression Treatment Protocol Combining Psilocybin and Cannabidiol

In a preclinical animal model, Wesana Health (WESA) found that a single high dose of psilocybin rapidly improved depressive behaviours for 14 days. A regimen of psilocybin microdoses and CBD was able to sustain the results and reduced depressive behaviours by an additional 64%.

Let’s keep the microdosing evidence coming!

PDF of article

Posted on

Slowing the progression of ALS

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

When diagnosed with ALS, patients are typically given 2 to 6 years to live and experience rapid decline in muscle function. Even after the ice bucket challenge took the internet by storm, a cure has yet to be found. 

Luckily, ketamine is showing potential to slow the progression of the disease to improve both the quality and length of patients’ lives.

In a mouse model of ALS, PharmaTher (PHRM) found that ketamine preserved muscle function and increased life expectancy if administered in the early stages of the disease. 

The company received FDA approval for a Phase II trial that will assess a biomarker of neurodegeneration, functional abilities, muscle strength, and depression scores among ALS patients undergoing ketamine treatments.

PharmaTher Inc.

PDF of article

Posted on

Psilocybin + CBD 🧠

Wesana Health Granted US FDA Pre-IND Meeting for SANA-013

The majority of patients with traumatic brain injury (TBI) also experience depression, and patients with severe TBI-related depression are 5x more likely to attempt suicide.

Wesana Health (WESA) is planning a study to see if the condition can be treated with one large dose of psilocybin in a clinic, followed by “self-administered maintenance doses” of psilocybin and CBD to sustain the benefits.

Researchers believe the treatment will promote neuroplasticity and neurogenesis while reducing neuroinflammation.

PDF of article

Posted on

Could this African shrub solve the opioid crisis?

MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC

MindMed (MNMD) developed a non-hallucinogenic molecule based on ibogaine, the psychoactive compound in the African iboga plant, and it’s showing potential to treat opioid addiction.

How? đŸ€”

The compound has demonstrated the ability to reduce opioid use and ease withdrawal symptoms by regulating excessive dopamine fluctuations.

An upcoming Phase 2a trial will put the compound to the test.

PDF of article

Posted on

Microdoses for the whole family

Mindset Pharma Announces Filing of International Patent Application Covering its Family 3 “Microdose” Compounds

Here’s a fun way to bond with grandma


Mindset Pharma (MSET) filed a patent for psilocybin microdoses that have potential to treat Alzheimer’s disease and ADHD. 

The compounds may promote cognitive benefits without the liability of a psychedelic experience, making them suitable for “fragile population groups” like children and the elderly, according to the company’s Chief Scientific Officer.

PDF of article